Condition
Systemic Sclerosis
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 85 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownImmun4Cure Cohort of Autoimmune DiseasesNCT07515638 · 2026-06-23
RECRUITINGExploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune DiseasesNCT07558850 · 2026-05-10
RECRUITINGUmbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.NCT06947473 · 2026-03-18
RECRUITINGA Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune DiseasesNCT07284797 · 2026-02-24
RECRUITINGExploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune DiseasesNCT07246096 · 2026-02-20
RECRUITINGA Study of AZD0120 in Autoimmune DiseasesNCT07295847 · 2026-01-09
RECRUITINGEACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular DiseasesNCT07077304 · 2025-11-19
RECRUITINGExploratory Clinical Study on YTS109 Cell Therapy for Autoimmune DiseasesNCT07236801 · 2025-11-13
RECRUITINGCD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAHNCT06947460 · 2025-04-18
RECRUITINGA Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)NCT06733935 · 2024-11-04
RECRUITINGClinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune DiseasesNCT06548607 · 2024-09-14
RECRUITINGFourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)NCT06350110 · 2024-07-10
RECRUITINGSearch for Diagnostic and Prognostic Biomarkers in Systemic Sclerosis and Inflammatory MyopathiesNCT04917705 · 2021-11-25
RECRUITINGRheumatology Patient Registry and BiorepositoryNCT04402086 · 2020-08-04
RECRUITINGDeployment o the Multidisciplinary Prospective Cohort ImminentNCT04334031 · 2020-07-20
RECRUITINGAutologous Stem Cell Transplantation in Patients With Systemic SclerosisNCT03630211 · 2018-07-31
RECRUITINGMeir Medical Center Rheumatologic BiobankNCT03473912 · 2018-04-16
RECRUITINGNew Orleans Pulmonary Hypertension BiobankNCT03269630 · 2017-12-29
RECRUITINGA Phase 1b Study of C-CAR168 in Participants With Systemic Sclerosis (SSc)NCT07854483 · 2027-03-01
NOT_YET_RECRUITINGA Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune DiseasesNCT07782450 · 2026-11-19
NOT_YET_RECRUITINGHyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung Disease and Systemic SclerosisNCT07821398 · 2026-11-01
NOT_YET_RECRUITINGA Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the BodyNCT07649265 · 2026-09-15
NOT_YET_RECRUITINGExtracellular Vesicle Dynamics Predicting Vascular Complications and Treatment Response in Systemic SclerosisNCT07717060 · 2026-09-01
NOT_YET_RECRUITINGInflammatory Disease Biobank for Immunophenotyping and Cardiovascular ResearchNCT07737470 · 2026-09-01
NOT_YET_RECRUITINGCD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune DiseasesNCT07596680 · 2026-09-01
NOT_YET_RECRUITINGA Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard TherapyNCT07676266 · 2026-07-01
NOT_YET_RECRUITINGA Study of CD19 UCAR-T Cells in Subjects With Autoimmune DiseasesNCT07212322 · 2026-01-30
NOT_YET_RECRUITINGEarly Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune DiseasesNCT06970951 · 2025-05-18
NOT_YET_RECRUITINGMesenchymal Stem Cells Infusion in Patients With Autoimmune DiseasesNCT06888973 · 2025-02-01
ENROLLING_BY_INVITATIONClinical Study on Targeted CD19CAR-T Therapy for Autoimmune DiseasesNCT06549296 · 2024-09-13
SUSPENDEDIntegration of Remote Monitoring in the Management of Chronic Immunosuppressive TherapyNCT06544343 · 2024-07-01
UNKNOWNThe Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune DiseasesNCT06420154 · 2024-05-27
NOT_YET_RECRUITINGPreliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune DiseasesNCT06417398 · 2024-05-14
UNKNOWNAn Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune DiseaseNCT06379646 · 2024-04-24
UNKNOWNAnti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune DiseaseNCT06373081 · 2024-04-20
UNKNOWNA Study of MK-2225 in Healthy Participants (MK-2225-003)NCT06643390 · 2023-11-21
COMPLETEDA Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)NCT05869955 · 2023-09-13
ACTIVE_NOT_RECRUITINGRecombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic DiseasesNCT05879419 · 2023-05-23
ACTIVE_NOT_RECRUITINGUniversal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune DiseasesNCT05859997 · 2023-05-17
ENROLLING_BY_INVITATIONRheumatology-based Adaptive Intervention for Social Determinants and Health EquityNCT05715463 · 2023-03-01
ACTIVE_NOT_RECRUITINGA Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic SclerosisNCT05462522 · 2023-01-16
COMPLETEDEfficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAHNCT05339087 · 2022-10-24
TERMINATEDOccupational and Environmental Causes of Autoimmune DiseasesNCT07000903 · 2022-05-10
COMPLETEDCOvid-19 Vaccine Booster in Immunocompromised Rheumatic DiseasesNCT05236491 · 2022-03-09
UNKNOWNExercise in People With Systemic SclerosisNCT05234671 · 2021-09-01
COMPLETEDStructural and Functional Impairment of Multiple Organs in Patients With Systemic Sclerosis: A MR Imaging StudyNCT05297474 · 2021-07-01
UNKNOWNA Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic SclerosisNCT04744207 · 2020-12-29
COMPLETEDClinical Risk Assessment of Cognitive Function in Systemic Autoimmune DiseasesNCT06029335 · 2020-09-01
UNKNOWNIs a History of Pre-eclampsia a Risk Factor for Vascular Phenotype in Women With Systemic Sclerosis?NCT04363021 · 2020-07-06
COMPLETEDCell Surface Marker Expression in Autoimmune DiseasesNCT03757065 · 2019-06-12
COMPLETEDObjective Measurement Methods for Autoimmune Disease and Dry Eye SyndromeNCT03937271 · 2019-04-01
WITHDRAWNA Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic SclerosisNCT03798366 · 2019-01-14
COMPLETEDA Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and DermatomyositisNCT03817424 · 2018-12-13
COMPLETEDVolatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)NCT03819777 · 2018-03-01
UNKNOWNA Systematic Review of Factors Associated With Pulmonary Arterial Hypertension in Systemic SclerosisNCT03889509 · 2018-03-01
COMPLETEDYellow Fever Vaccine in Patients With Rheumatic DiseasesNCT03430388 · 2018-01-31
COMPLETEDA Study of KHK4827 in Patients With Systemic SclerosisNCT04368403 · 2017-10-06
COMPLETEDPulmonary Hypertension Screening for Rheumatology Patients (SOPHIE)NCT03446339 · 2017-08-03
UNKNOWNEcho Systemic SclerosisNCT03143413 · 2017-03-24
UNKNOWNDimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial HypertensionNCT02981082 · 2016-12-01
TERMINATEDCommon interventions
PlaceboDRUG6PlaceboOTHER4CyclophosphamideDRUG3Doppler ultrasoundRADIATION3AmbrisentanDRUG2FludarabineDRUG2AlemtuzumabDRUG1Anti Thymocyte GlobulinDRUG1anti-CD19-CAR-T cellsBIOLOGICAL1Anti-CD19-CD3E-CAR-T cellsBIOLOGICAL1anti-CD19/BCMA U CAR T cellsBIOLOGICAL1anti-CD19/BCMA-UCAR-T cellsBIOLOGICAL1AZD0120BIOLOGICAL1Biobanking with genetic analysisGENETIC1Blood SampleOTHER1Blood sample collectionOTHER1Blood sampling, nailfold capillaroscopyDIAGNOSTIC_TEST1Blood test and principal collectionBIOLOGICAL1BosentanDRUG1Bosentan 125 mgDRUG1Bosentan 62.5 mgDRUG1BRL-301BIOLOGICAL1C-CAR168BIOLOGICAL1CC-97540DRUG1CD19 or CD19-BCMA CAR-TDRUG1
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
Assistance Publique - Hôpitaux de Paris
4
Echosense Ltd.
4
Nanjing Bioheng Biotech Co., Ltd.
3
Actelion
2
Beijing GoBroad Hospital
2
China Immunotech (Beijing) Biotechnology Co., Ltd.
2
Heidelberg University
2
Louisiana State University Health Sciences Center in New Orleans
2
Medical University of Graz
2
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
2
University Hospital, Lille
2
University of Pecs
2
University of Sao Paulo General Hospital
2
AbelZeta Inc.
1
Alpine Immune Sciences, Inc.
1
Trial status mix
COMPLETED28
RECRUITING18
UNKNOWN14
NOT_YET_RECRUITING11
TERMINATED5
ACTIVE_NOT_RECRUITING3
WITHDRAWN3
ENROLLING_BY_INVITATION2
SUSPENDED1
Phase mix
NA19
PHASE119
PHASE214
EARLY_PHASE17
PHASE33
PHASE43
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.